Moleculin Biotech, Inc. 8-K

What Happened

• Moleculin Biotech, Inc. filed a Form 8-K on May 12, 2026 (Item 7.01) to disclose a press release announcing the publication of an abstract at the European Hematology Association (EHA) 2026 Congress. The abstract highlights the cardiac safety profile of Annamycin (also reported in journals as L‑Annamycin), the company’s next‑generation anthracycline in late‑stage development for relapsed/refractory acute myeloid leukemia (R/R AML). The press release is included in the filing as Exhibit 99.1.

Key Details

• Filing date: May 12, 2026 (Form 8-K, Item 7.01 Regulation FD disclosure).
• Event: Publication of an abstract at EHA 2026 Congress announcing cardiac safety data.
• Drug: Annamycin (L‑Annamycin), described as a next‑generation anthracycline in late‑stage development for R/R AML.
• Exhibits: Press release attached as Exhibit 99.1; cover page interactive data file included as Exhibit 104.

Why It Matters

• Cardiac safety is a key concern for anthracycline drugs; published safety data can affect clinical development, regulatory review, physician and patient confidence, and investor perception.
• This filing is a Regulation FD disclosure (public release of material information) rather than an earnings, executive-change, or merger disclosure, so it signals clinical development progress rather than financial or corporate leadership news.